قراءة
عرض

Haematology

Dr Khudhair Abass Ali
College of Medicine – Baghdad University

Objectives L7

Hematological malignancies: Acute Leukemias:
Lymphoblastic(ALL),Myeloblastic(AML)

Chronic Leukemias:

Myeloblastic(CML),Lymphoblastic(CLL)

Haematological Malignancies

Corruption of the processes controlling proliferation & apoptosis of bl. Cells.
If mature cells involved → Chronic Leukemia or Low grade Lymphoma
Primitive cells involved → Acute Leukemia or High grade Lymphoma
Leukemias : 100/ 100 000 /y .Acute Leukemia ˂ 50 % M ˃ F ,
Acute: All ages , ALL ↑ in children, AML ↑ in Old.
Risk Factors : 1. Ionizing radiation
2. Cytotoxic drugs
3.Retroviruses.
4.Genetics
5.Immunological.


Lecture (7)

Acute Leukemia : ALL & AML

Failure of cell maturation, accumulation Of useless immature cells in B.M. on the
expense of normal haemopoeitic elements, with spilling of immature cells into Bl.
Clinical Features are: marrow failure ( Anemia, Bleeding, or Infection)
Investigations :
CBP : Anemia ,WBC : ↓ 1 X 10 9/ L --- ↑ 500 X 10 9/ L (Majority ˂ 100 X 10 9/L. Platelets : usually very low.
BLAST in Peripheral Blood .
BM : Confirm the diagnosis, replacement of normal elements by leukemic
blast cells ( ˃ 20 % of the cells ),presence of Auer rods in the cytoplasm
of the blast cells = AML.
Management :
1. Decide whether to give specific treatment or not,(It is aggressive with ↑S.E.)
which may not be appropriate for elderly or patients with other serious dis.→ supportive treatment.



Hematological malignancies





Hematological malignancies




Hematological malignancies




Hematological malignancies

Specific Treatment :

Preparation for specific treat. :
1.Identify & treat infection
2.Correct Anemia :Red cell Concentrate.
3.Thrombocytopenic bleeding ← Platelets'.
4.Hicman line (if possible)
5.Explain Therapeutic regimen to pt. & obtain consent.
-Aim of Treat. = destroy leukemic cells without destroying the normal stem cells
→Repopulation of haemopoeitic Ts.
Remission induction :Bulk of tumor is destroyed by combination chemotherapy
→Severe bone marrow hypoplasia (require intensive support.)
Remission consolidation :If Rem. Achieved → Residual dis. attacked by No. of courses of chemo.→ marrow hypoplasia (BMT may be included at this stage)
Rrmission maintenance :If still in Rem.(ALL) → Repeated cycles of Chemo. up to 3yr.
+ CNS prophylaxis = Intathecal (IT) Methotrexate + cranial radiation.
Failure of Rem. in induction. →Alternative combination of drugs.(poor prognosis)
Relapse during treat. Or after → poor prognosis.


Drugs commonly used in treat. Of Acute Leukaemia
phase ALL AML
Induction Vivcristine (iv) Daunorubicine(iv)
Prednisolone(po) Cytarabine(iv)
L-asparaginase(im) Etoposide(iv&po)
Daunorubicine(iv)
Methotrexate(IT)
Consolidation Daunorubicine(iv) Cytarabine(iv)
Cytarabine(iv) Amsacrine(iv)
Etoposide(iv) Mitoxantrone(iv)
Methotrexate(iv)
Maintenance Prednisolone(po)
Vincristine(iv)
Mercaotopurine(po)
Methotrexate(po)

Supportive treatment:

Anemia : Red Cell Concentrate Transfusion.
Bleeding :Thrombocytopenic bleeding require platelets.Prphylactic plat.transf.to
maintain plat.˃ 10 X 10 9/L. Treat any Coagulation abnormalities.
Infection : Fever ˃ 38oC , ˃ 1h in Neutropenic pt. indicate possible septicemia. Start
Broad spectrum antibiotic(Gentamycin + piperacillin± Vancomycin),to continue for at least 3ds after the fever resolved.
Flucanazole for oral & pharyngeal moniliasis.
Amphotericin iv for systemic fungal inf.(candida or aspergillosis) for 3wks.
Herpes simplex and zoster : antiviral(aciclovir).
Isolation is debatable (psychological).
Metabolic problems :Monitor fluid, hepatic, renal function,anorexia & difficult drinking
→ iv fluid & electrolytes. Cellular breakdown during induction(tumor lyses'
syndrome) → ↑K, ↑Uric acid, ↑phosphate,& ↑Ca. → RF ?
Allopurinol + iv Hydration .
Psychological : Keep pt. informed ,answer question, allay fear as possible.
Prognosis : Median survival without treat.is 5wks….Few Ms with supportive treatment.
80% ˂ 60y age achieve remission with specific treat.
Survival depends on risk factors (chromosomal analysis)
5y survival for AML 21%-76%, ALL 20-37% .


Chronic Myeloid Leukemia ( CML )
* Myeloproliferative stem cell disorder resulting in prolif. Of all hematopoietic
Lineage but predominantly in the granulocytes series. Chiefly 30-80y, 20% of all
leukemia. * 95% have Philadelphia (ph ch) = shortened ch. 22 resulting from translocation
of material with ch 9.
* BCR(breakpoint cluster region on chr.22 + Fragment from chr. 9 carries ABL oncogen → BCR ABL Gene codes for protein with Tyrosine Kinas activity→ play a role in the dis. As an oncogen.
CML has 3 phases:
1.Chronic phase:. The dis. is responsive to treat., lasting 3-5y. With the introduction of imatinib → ˃ 5Y.
2.Accelerated phase :(not always seen), dis. control more difficult.
3.Blast crises:dis transforms into acute leukemia (AML%70 ,ALL30%),Refractory to
treat., It is the major cause of death. Prior to imatinib therapy, 10% CML→ AML/y, now only 0.4-2.5% after up to 5y treatment with imatinib.
ph. Ch. –ve CML: 0ld pt., ↑Male, ↓Plat. ↑ Monocyte,respond poorly to treat.
Median survival 1y.


Hematological malignancies

Clinically: 25% - asymptomatic at diagnosis.

Tiredness 37% Anorexia 12%
SOB 21% Abdom. Fullness 10%
Abdom. Pain 21% Bruising 7 %
Lethargy 13% Vague ill health 7%
*Splenomegally 90% (10% massive) ± friction rub(splenic infarction)
*Hepatomegally 50%
*LN Unusual.
Investigations:1.FBC: An.(normochromic normocytic).WBC 10-600X10 9/L(full range
of granulocytes precursors from myeloblast to mature neutrophils,
myeloblast ˂ 10%, ↑Eosinoph .&Basophils.
Platelets: ↑ in ⅓ (up to 2000x109/L . Nucleated RBC are common.
Accelerated phase: ↑ % of more primitive cells.
Blast transformation: Dramatic ↑ Blast in circul., ↓plat.
Basophils ↑ with dis. Progress.
2. Bone marrow: to confirm diagnosis &phase of the dis.(morphology & chromosome analysis .
3. Bl. LDH & Uric acid ↑ ( ↑ cell breakdown)


Management:
Chronic phase:1.Imatinib inhibit BCR ABL Tyrosine Kinase(TK) activity & reduce
. the uncontrolled prolif.of WBC.. It is Ist line therapy in chronic phase
complete cytogenic response (disappearance of ph chr.) in 76% at 18 Ms of therapy.
Failure of response or progress on imatinib → 2nd generation TK Inh. e.g.
Dasatinib, or Nilotinib : 2. Allogenic BMT
3. Hyroxycarbamide (Hydroxyurea):still used for initial control of the dis.or
palliative treat.(no effect on ph chr. & on onset of blast transformation).
4. Interferon-ἀ : was Ist line of treat.± Ara-C: control CML in 70% of cases.
Accelerated phase: Pt. presented with this phase ,imatinib is indicated if not already
received. Hydroxyurea is also effective. Low dose cytarabine can be trie Blast Transform.: ALL response better than AML.( + supportive treat.)
Pts. Progressing to advanced phase on imatinib may respond to 2nd genera. TK inh. or BMT.

Chronic Lymphocytic Leukemia (CLL)

* Most common leukemia(30%).M:F is 2:1, median age at presentation 65-70y.
* B lymphocytes fail to transform & produce Abs →Increasing mass of immuno-
incompetent cells → ↓immune function & normal BM haematopoeisis.
Clinically:
*insidious onset. 70% incidental diagnosis (routine FBC).
*Anemia, Infection, Painless Lymphadenopathy ± splenomegally & systemic symptoms e.g.Night sweat ,or wt. loss.
Investigations:
1.FBC: Mature lymphocytes ˃ 5x 10 9/L. characteristic morphology & markers, CD19 & CD23.
2.↑ Reticulocyte count & +ve coombs test.= haemolytic An.(may occur)
3.S. Igs: to assess the degree of immunosuppression(common & progressive).
4.B.M. exam. Is not essential for diagnosis, but helpful for prognosis(diffuse involve.= poor prognosis),& to monitor response to therapy.
Main prognostic factor is stage of the dis.,CD38 ,Mutation of IgVH Genes suggest poor prognosis.
Staging of CLL:
Stage A: 60%,No anemia, Normal Plat. Count, ˂ 3 areas of LN enlargement.
Stage B: 30%,No anemia, Normal Plat., 3 or more areas of LN enlarg.
Stage C : 10%,Anaemia & or ↓ Plat., regardless of the No. of areas of LN enlarg .



Hematological malignancies




Hematological malignancies

Management:

* No specific treat. For most stage A, unless progression, life expectancy is normal in
most patients.

*Treatment: Indications: 1. BM failure. 2. Massive or progressive LN PATHY or Splenomegally.
3. Systemic symptoms e.g. wt. loss or night sweat.
4. Rapidly ↑ lymphocyte count.
5. Autoimmune haemolytic An.,or ↓ Plat.
Stage B & C :Chlorambucil
Recently Fludarabine + Cyclophosphamide → ↑ rem.rates & dis. Free survival ( ↑ risk of infection )
B.M. Failure or autoimmune cytopenias → corticosteroid.
Supportive care: Symptomatic, Anemia or thrombocytopenia → Transfusion.
Treat. Of infect., Ig for hypogammaglobulinaemia.
Radiotherapy: LN causing discomfort or obstruction.& for symptomatic splenomegaly Splenectomy : may be , to improve low Bl. Count. due to autoimmune destruction or due to hypersplenism & can relieve massive splenomegally.
* Prognosis: Overall survival is 6y., stageC 2-3y, ,50% die from infection.
Rarely → Aggressive high grade Lymphoma(Richters syndrome).

Prolymphocytic Leukemia

* Variant of CLL, mainly in Male ˃ 60y. 25% T cell variety
* Massive splenomegaly, + Little Lymphadenopathy.
* WBC often ˃ 400 x 10 9/ L (Characteristic cell is large lymphocyte with prominent nucleolus.
* Treat. : Is generally unsuccessful & prognosis very poor.
Leukapharesis, Splenectomy, & chemo. May be tried.

Hairy cell Leukemia :

* Rare,chronic lymphoproliferative B cell disorder, M 6:F 1 , median age 50y.
* General ill health, & recurrent infection.
* Splenomegaly 90%, LN unusual.
* Lab.: Severe Neutropenia, Monocytosis,& characteristic HAIRY CELL in Bl. & B.M..
→ CD25 & CD103.
* Treat.: Cladribine & Deoxycoformycin.



Hematological malignancies





Hematological malignancies

Summary

Acute leukemias: ALL & AML
Failure of maturation.
Lab: > 20% Blast.in BM.
R: Supportive or aggressive
CML:↑profil. Of all haemopo.cells.
90% +ve ph chr.
3 phases: Acute, Accelerated, Blast.
R:Imatinib
CLL: B Lymphocytes fail to transform & produce Ab.
3 stages.
R:Fludarabine



رفعت المحاضرة من قبل: AyA Abdulkareem
المشاهدات: لقد قام 169 عضواً و 372 زائراً بقراءة هذه المحاضرة








تسجيل دخول

أو
عبر الحساب الاعتيادي
الرجاء كتابة البريد الالكتروني بشكل صحيح
الرجاء كتابة كلمة المرور
لست عضواً في موقع محاضراتي؟
اضغط هنا للتسجيل

Title

Text